NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









InCarda Therapeutics

InCarda Therapeutics

Private
West Jordan, UtahHealthcare & Life Scienceshttps://www.incardatherapeutics.com/

Last Round

Series D

Jun 15, 2022

Total Funding Raised

$77.56M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

InCarda Therapeutics is a biopharmaceutical company that develops innovative inhaled therapies for the targeted treatment of cardiovascular conditions, including paroxysmal atrial fibrillation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

atrial fibrillationAFibinhaled therapyflecainidecardioversiondrug deliverybiopharmaceuticalclinical trialmedical deviceinhalation technologyacute carenon-invasive treatmentdigital healthremote patient monitoring

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InCarda Therapeutics Comparables

Compare InCarda Therapeutics with similar companies based on industry and business-model similarity.

InCarda Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HUYA Bioscience International
78%
Acesion Pharma
77%
Philip Morris International
73%

InCarda Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJun 15, 2022
Series COct 21, 2020
Series BNov 8, 2018
Series AApr 28, 2015
Private PlacementDec 5, 2014
Debt
Aug 28, 2013

Key People

Founding team and executive leadership

Carlos Alejandro Schuler

Chief Technology Officer And Co-founder

Founding Team

Narsi R.

Chief Business Officer And Co-founder (Consulting)

Founding Team

InCarda Therapeutics Investors

Notable investors and investment history

InCarda Therapeutics investors
InvestorRounds
Deerfield ManagementSeries B, Series C
Morningside VenturesSeries B, Series C, Series A
InnovivaSeries D, Series C
Asset Management VenturesSeries B
HealthCapSeries C, Series B
Morningside GroupSeries B, Series C, Series A
Sofinnova InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 39% MoM.

  • Apr 17, 2026

    Monthly visitors increased 54% MoM.

InCarda Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InCarda Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InCarda Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWest Jordan, Utah
Employee Range11
Year Founded2009
Last FundingJun 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.